Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (141-150 of 391) with videos related to

Pageof 40
Sort By:
Respiration; International Review of Thoracic Diseases|February 8, 2018
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary FibrosisMichael Kreuter, Ulrich Costabel, Luca Richeldi, et al.
Journal of Comparative Effectiveness Research|December 20, 2022
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Advances in Therapy|October 27, 2015
Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi TechniqueToby M Maher, Moira K B Whyte, Rachel K Hoyles, et al.
ACR Open Rheumatology|July 19, 2022
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled TrialShervin Assassi, Oliver Distler, Yannick Allanore, et al.
BMJ Open Respiratory Research|September 21, 2018
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
Pharmacology & Therapeutics|December 28, 2020
Idiopathic pulmonary fibrosis: Disease mechanisms and drug developmentPaolo Spagnolo, Jonathan A Kropski, Mark G Jones, et al.
The European Respiratory Journal|May 18, 2013
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway FibrosisLuca Richeldi, Harold R Collard, Roland M du Bois, et al.
Thorax|March 4, 2014
Case-based discussion from the Royal Devon and Exeter NHS Foundation Trust: a painful paradoxCharles Sharp, Manish Powari, Ravik Mascarenhas, et al.
The European Respiratory Journal|January 28, 2012
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapyGregory J Keir, Toby M Maher, David M Hansell, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Pageof 40

Showing results (141-150 of 391) with videos related to

Sort By:
Pageof 40
Respiration; International Review of Thoracic Diseases|February 8, 2018
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary FibrosisMichael Kreuter, Ulrich Costabel, Luca Richeldi, et al.
Journal of Comparative Effectiveness Research|December 20, 2022
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Advances in Therapy|October 27, 2015
Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi TechniqueToby M Maher, Moira K B Whyte, Rachel K Hoyles, et al.
ACR Open Rheumatology|July 19, 2022
Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled TrialShervin Assassi, Oliver Distler, Yannick Allanore, et al.
BMJ Open Respiratory Research|September 21, 2018
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
Pharmacology & Therapeutics|December 28, 2020
Idiopathic pulmonary fibrosis: Disease mechanisms and drug developmentPaolo Spagnolo, Jonathan A Kropski, Mark G Jones, et al.
The European Respiratory Journal|May 18, 2013
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway FibrosisLuca Richeldi, Harold R Collard, Roland M du Bois, et al.
Thorax|March 4, 2014
Case-based discussion from the Royal Devon and Exeter NHS Foundation Trust: a painful paradoxCharles Sharp, Manish Powari, Ravik Mascarenhas, et al.
The European Respiratory Journal|January 28, 2012
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapyGregory J Keir, Toby M Maher, David M Hansell, et al.
The New England Journal of Medicine|May 15, 2022
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
Pageof 40